Atara Biotherapeutics, Inc.
For the period ended Dec 31, 2025. Filed Mar 16, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 16, 2026
ATRA$8.18+3.9%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Balance Sheets
(In thousands, except per share amounts)
| December 31, | December 31, | |
|---|---|---|
| 2025 | 2024 | |
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $8,482 | $25,030 |
| Short-term investments | — | 17,466 |
| Restricted cash | — | 146 |
| Accounts receivable | 1,253 | 1,482 |
| Inventories | — | 10,655 |
| Other current assets | 2,477 | 10,115 |
| Total current assets | 12,212 | 64,894 |
| Property and equipment, net | 73 | 1,294 |
| Operating lease assets | 7,064 | 39,807 |
| Other assets | 886 | 3,103 |
| Total assets | $20,235 | $109,098 |
| Liabilities and stockholders’ equity (deficit) | ||
| Current liabilities: | ||
| Accounts payable | $127 | $4,367 |
| Accrued compensation | 1,271 | 6,589 |
| Accrued research and development expenses | 82 | 7,984 |
| Deferred revenue | 716 | 95,092 |
| Liability related to the sale of future revenues – current portion | 9,750 | 382 |
| Other current liabilities | 2,976 | 20,160 |
| Total current liabilities | 14,922 | 134,574 |
| Operating lease liabilities – long-term | 9,347 | 29,914 |
| Liability related to the sale of future revenues – long-term | 32,673 | 38,624 |
| Other long-term liabilities | 1,795 | 3,269 |
| Total liabilities | 58,737 | 206,381 |
| Commitments and contingencies (Note 9) | ||
| Stockholders’ equity (deficit): | ||
| Common stock—$0.0001 par value, 500,000 shares authorized as of December 31, 2025 and 2024, respectively; 7,324 and 5,859 shares issued and outstanding as of December 31, 2025 and 2024, respectively | 1 | 1 |
| Additional paid-in capital | 1,983,361 | 1,957,261 |
| Accumulated other comprehensive income | 1 | 8 |
| Accumulated deficit | (2,021,865) | (2,054,553) |
| Total stockholders’ equity (deficit) | (38,502) | (97,283) |
| Total liabilities and stockholders’ equity (deficit) | $20,235 | $109,098 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.